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qualitative researchAfter decades of neglect, the field of tuberculosis
(TB) diagnostics is advancing. New tests have been
developed and evaluated, existing ones are being
adapted for new contexts, and decision-makers
have a rich pipeline to choose from and invest in
[1]. Yet, some important gaps remain, including
the need for a simple, point-of-care (POC) test
[2].
In order to be able to develop, validate, and
scale-up diagnostics, a thorough assessment of
the context and settings of use at the different
points of care is necessary. This requires re-
search approaches that are able to take into ac-
count processes and reveal complex relationships
and patterns involved in making diagnostics work
in the real world. Qualitative research ap-
proaches are ideally suited for this. They offer
a range of methodologies, such as in-depth inter-
views, focus group discussions, participant obser-
vations and discourse analysis, that can make
sense of processes and meanings in their natural
settings, and answer the how and why questions
[3].
Yet, qualitative research on TB diagnostics is
scarce. The few published studies have mainly
focused on how stigma and disease perceptions
influence healthcare seeking and diagnosis [4,5],
reasons for delay in healthcare seeking [5–7]
and what it means to live with TB diagnosis
[8]. Such studies generate important insights for
test developers, and more research is needed
into patient needs and pathways to diagnosis.
Yet, it does not make use of the full potential
of qualitative research for answering the most
pressing questions of the TB diagnostics
community.2210-6006/$ - see front matter c 2013 Ministry of Health, Saudi Ar
http://dx.doi.org/10.1016/j.jegh.2013.04.0021. How to take into account complex
diagnostic ecosystems?
New diagnostic tests need to function in a complex
ecosystem of different users (patients, healthcare
providers, laboratory technicians, communities,
manufacturers, suppliers, and policymakers) at dif-
ferent levels of healthcare systems. In developing
new tests, we might need a variety of different tar-
get product profiles and business models to do jus-
tice to different settings of use, i.e. hospital,
clinic, peripheral laboratory, community and home
[9]. This can be further complicated in settings
that have a multiplicity of providers, incentive
mechanisms and the absence of clear regulations
(e.g. India) [10]. It is unclear how to shorten time
delay in the diagnosis of TB, ensure links to rapid
and correct treatment regimens and make tools
fit to different user needs and settings. Qualitative
research can generate a thorough understanding of
these systemic issues and how regulatory, eco-
nomic, epidemiological, behavioral, socio-cultural,
technical, clinical, and political aspects interrelate
in existing diagnostic processes.
2. How to scale-up and combine new and
existing diagnostic tests in routine
programs?
As new TB diagnostics become available, it can be
challenging to ensure a successful scale-up at the
country level and combine new tests with existing
algorithms [11]. How do governments and TB con-
trol programs make choices about new tools? Why
do some tests get scaled-up while others do not?abia. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.
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health providers actually use them to make rapid
decisions about TB treatment? Such questions will
require, among others, understanding the role
diagnostic tests play in patient–practitioner inter-
actions, as part of comprehensive care and in com-
bination with other diagnostic technologies and
clinical decision-making. Qualitative research can
examine underlying processes and meanings in-
volved in diagnosing TB, and render visible the var-
ied aspects involved in making a diagnostic
technology work.
3. How to actively manage and foster
innovation for TB diagnostics at the
country level?
It is unclear what different policymakers and actors
along the value chain need, what evidence is re-
quired, and how decisions are being made [12].
Qualitative research can examine the needs of dif-
ferent stakeholders in decision-making and evalua-
tion processes. For example, test developers need
to understand what the unmet needs are, as well as
potential barriers for scale-up of tests [13] and
qualitative research can provide the answers.
4. How to assess tests and evaluate their
impact?
There is an increasing recognition that test accu-
racy studies and expert opinions are insufficient
for policy and scale-up decisions [14]. We need
data on the impact of the test on important out-
comes of patients, on diagnostic decision-making,
and on public health outcomes (e.g. reduction in
TB incidence). Calls have been made for more
implementation, operational and health systems
research [2,15]. Several frameworks, such as the
impact assessment framework by Mann et al.
[16], or the technical and programmatic recom-
mendations required for policy recommendations
on new TB diagnostics [17] are emerging that can
support collecting this kind of evidence. These
frameworks have in common the fact that they ac-
count for the contexts in which diagnostic tests
have to function in and employ a range of methods,
including qualitative research.
Our own work in India shows the potential of
qualitative research to study the processes of
adapting and testing a new TB diagnostic device
in its intended setting of use [18], and why inaccu-
rate blood antibody tests are so popular in the pri-
vate health sector [10]. Further inspirations for
qualitative research in TB diagnostics can also bedrawn from experiences with qualitative methods
in medical device design (design ethnographies)
with emerging frameworks specifically for diagnos-
tic tests [19,20], in health technology assessment
[21] and alongside clinical trials [22].
5. Why is qualitative research under-
used in the field of TB?
Qualitative research often involves fieldwork which
can vary in its duration and extent (from months to
years). Data collection techniques can be orga-
nized cost-effectively, but involve dedicated hu-
man resources with (substantial) time and
capacity for data collection and analysis. Another
hesitation stems from the concern to reach statis-
tical generalizations. Contrary to quantitative
methods, qualitative methods aim at analytical
not statistical generalization. Lastly, publication
barriers might discourage researchers. Medical
journals, editors and reviewers may undervalue
publications with qualitative results. Instead of
focusing on a false dichotomy between quantita-
tive and qualitative methods, they should focus
on which approach and methodologies are required
to solve a particular problem [3].
Overall, the challenges that the TB community
faces are too urgent and complex to exclude
potentially valuable research methodologies. We
need more qualitative research to support innova-
tors of TB diagnostics in developing better prod-
ucts, and TB controllers and policy-makers to
translate products into showing an impact on
health.
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